Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Dec 10;116(50):24922-24924.
doi: 10.1073/pnas.1918897116. Epub 2019 Nov 25.

Remyelination and the gut-brain axis

Ian D Duncan  1 , Jyoti J Watters  2
Affiliations
Comment

Remyelination and the gut-brain axis

Ian D Duncan et al. Proc Natl Acad Sci U S A. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interest.

Figures

Fig. 1.
Fig. 1.
Remyelination is not enhanced by microbiome manipulation. A schematic of the gut microbiome−brain axis tested in the study by McMurran et al. (11). The authors used germ-free mice, or specific pathogen-free mice in which the intestinal microbiota were depleted with antibiotics or skewed with probiotics, in order to study the effects of the microbiome on remyelination. Two models of toxicity-induced demyelination were used: 1) focal demyelination in the ventral thoracic spinal cord induced by lysolecithin injection and 2) oral cuprizone-induced demyelination in the corpus callosum. The abundance of myelin debris within demyelinated lesions, the prevalence of homeostatic versus degeneration-associated microglia, the frequency of both OPCs and differentiated oligodendrocytes, and the density of remyelinated axons were assessed. The results show that, while microbiome manipulation alters the numbers of homeostatic and degeneration-associated microglia within the demyelinated lesion differently depending upon the model tested, neither OPC proliferation nor oligodendrocyte differentiation are impacted in any model, nor is remyelination enhanced.
See this image and copyright information in PMC

Comment on

References

    1. Reich D. S., Lucchinetti C. F., Calabresi P. A., Multiple sclerosis. N. Engl. J. Med. 378, 169–180 (2018). - PMC - PubMed
    1. Trapp B. D., Nave K. A., Multiple sclerosis: An immune or neurodegenerative disorder? Annu. Rev. Neurosci. 31, 247–269 (2008). - PubMed
    1. Stadelmann C., Wegner C., Brück W., Inflammation, demyelination, and degeneration - Recent insights from MS pathology. Biochim. Biophys. Acta 1812, 275–282 (2011). - PubMed
    1. Lassmann H., Mechanisms of white matter damage in multiple sclerosis. Glia 62, 1816–1830 (2014). - PubMed
    1. Franklin R. J. M., Ffrench-Constant C., Regenerating CNS myelin—From mechanisms to experimental medicines. Nat. Rev. Neurosci. 18, 753–769 (2017). - PubMed

Publication types

LinkOut - more resources